Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on November 15, 2021, reporting events occurring on November 12 and November 15, 2021. The filing serves to disclose the Company's financial results for the quarter ended September 30, 2021, and the posting of an updated corporate presentation.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No specific material changes in financial condition or operations are quantified in this document. The filing indicates that the Company announced its Q3 2021 results via a press release on November 12, 2021.
Guidance, Outlook, and Risks
- Outlook: The Company posted an updated corporate presentation on November 15, 2021, which may be used for future communications.
- Risks: The filing contains forward-looking statements based on current expectations. Actual results may differ materially due to risks and uncertainties.
- Legal Status: Information in this report and its exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific Q3 2021 financial results (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Review the updated corporate presentation (Exhibit 99.2) for strategic updates and future guidance.
- Confirm the distinction between the registrant name (Ocuphire Pharma, Inc.) and any external metadata references to other entities.
- Note that the forward-looking statements in the exhibits are subject to standard risk factors and are not guarantees of performance.